Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: A randomized placebo-controlled trial.
OBJECTIVE
Lipid abnormalities are regarded as a risk factor for cardiovascular disease. Low vitamin D status has been shown to be associated with hyperlipidemia. We planned to research the effects of vitamin D supplementation as an adjuvant therapy for patients with hypercholesterolemia.


METHODS
Patients with hypercholesterolemia were enrolled in this single-center, double-blind, placebo-controlled trial in Beijing (39°54' N). Fifty-six patients were randomly assigned to receive vitamin D (n = 28, 2000 IU/d) or a placebo (n = 28) as an add-on to statin, by the method of permutated block randomization. Serum lipid levels were evaluated at baseline, 1, 3 and 6 months.


RESULTS
Vitamin D supplementation resulted in increased serum 25-hydroxyvitamin D concentrations compared with placebo (+16.3 ± 11.4 compared with +2.4 ± 7.1 ng/ml; p < 0.001). At 6 months, the primary end point, a difference in the fall of serum total cholesterol levels between the vitamin D and placebo groups after 6 months of treatment was significant -22.1 mg/dl (95% CI -32.3; -12.2) (p < 0.001). The difference between the groups in the fall of serum triglyceride levels after 6 months of treatment was -28.2 mg/dl (95% CI -48.8; -8.4) (p < 0.001). In patients with 25-hydroxyvitamin D level<30 ng/ml at baseline (n = 43), the serum total cholesterol and triglyceride levels were reduced by -28.5 ± 11.9 mg/dl (p < 0.001) and -37.1 ± 19.5 mg/dl (p < 0.001), respectively.


CONCLUSIONS
Vitamin D supplementation might improve serum lipid levels in statin-treated patients with hypercholesterolemia, it might be an adjuvant therapy for patients with hypercholesterolemia. Clinical Trials Registration Number - NCT02009787.
Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Henan Province, China.
Xiao Fei
XF
Qin
Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Henan Province, China. Electronic address: zhaoluosha@126.com.
Luo Sha
LS
Zhao
Department of South-building Cardiology, PLA General Hospital at Beijing, China.
Wei Ren
WR
Chen
Department of South-building Cardiology, PLA General Hospital at Beijing, China.
Da Wei
DW
Yin
Department of South-building Cardiology, PLA General Hospital at Beijing, China.
Hao
H
Wang
D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D002784:Cholesterol / Q000097:blood*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood*; D014807:Vitamin D / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides; D014807:Vitamin D; D002784:Cholesterol
Adjuvant therapy; Hypercholesterolemia; Supplementation; Vitamin D